Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menú

Buscar estudios clínicos de BMS
Icono de BMS, estudio Completado

Completed

ID del estudio CC-90011-PCA-001  |   NCT04628988

A Study of CC-90011 and Comparators in Participants With Prostate Cancer

Ícono de advertencia
Este estudio clínico ya está completo.  Cuando estén disponibles, los resultados se publicarán en ClinicalTrials.gov
Ver los resultados del estudio
Puede comprobar si es una posible coincidencia para otro ensayo clinico haciendo clic en el boton "Verificar su Elegibilidad"
Verifique su elegibilidad

Descripción general

This is an open-label, positron emission tomography (PET) imaging Proof of Biology (POB) study to determine whether CC 90011 reverses, by the induction of androgen receptor (AR) expression, the castration resistance, due to lineage switch, in participants with mCRPC that have failed enzalutamide as last prior therapy. This study aims to assess whether CC-90011 can induce AR expression and, consequently, re-sensitize tumors to anti-hormonal therapy.

Ayúdenos a mejorar su experiencia en el sitio web. Comparta sus comentarios con nuestro equipo en BMS Clinical Trials para mejorar su experiencia y la de los demás. Gracias